© 2016 • Sabin Vaccine Institute • 2000 Pennsylvania Ave, NW, Suite 7100 • Washington, DC 20006 • t. (202) 842-5025
Wednesday, June 25, 2014
Sabin President Dr. Peter Hotez highlights the potential benefits a Hookworm vaccine would bring to the millions of people suffering from this neglected tropical disease.
"In fact, one-third or more of the children and women living below the World Bank poverty level are infected with hookworm resulting in a devastating disease burden from moderate and severe anemia. Our findings also show that these diseases disproportionately occur in the world's poorest Islamic countries -- nations such as Indonesia, Bangladesh, Mali, Nigeria, and several countries of the Middle East and North Africa.
The good news is that the Sabin Vaccine Institute's Product Development Partnership (Sabin PDP) is developing the world's first human hookworm vaccine, which could have a tremendous impact on the health, economic and social landscape of countries with high burdens of this disease."